Evaluation of the protein biomarkers and the analgesic response to systemic methylene blue in patients with refractory neuropathic pain: a double-blind, controlled study
Journal of Pain Research, 2015
Miclescu A., Svahn M., Gordh T.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Neurology | Patient Stratification | Plasma |  Olink Target 96 |
Abstract
This study was carried out in patients with neuropathic pain in order to assess the analgesic effects and changes in protein biomarkers after the administration of methylene blue (MB), a diaminophenothiazine with antioxidant and anti-inflammatory properties. Ten patients were included in the study. MB decreased the pain levels in patients 2 days after administration. Protein expression, except for PRL which decreased, was the same between the MB and the control group, hence MB infusion decreased the PRL level.